Influenza Diagnostic Market Report 2026

The influenza diagnostic market size has grown strongly in recent years. It will grow from $2.87 billion in 2025 to $3.1 billion in 2026 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to seasonal influenza outbreaks, widespread use of rapid antigen tests, growth of hospital laboratory infrastructure, government influenza surveillance programs, increased awareness of early flu diagnosis.

The influenza diagnostic market size is expected to see strong growth in the next few years. It will grow to $4.19 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to rising frequency of influenza epidemics, growing demand for accurate molecular diagnostics, expansion of point-of-care testing facilities, increased public health preparedness initiatives, technological advancements in rapid diagnostic assays. Major trends in the forecast period include rising demand for rapid influenza testing, increased adoption of molecular diagnostic methods, growing preference for point-of-care flu diagnostics, expansion of seasonal and pandemic surveillance testing, continuous improvement in test sensitivity and specificity.

The increasing allocation of research funding for influenza diagnostics is expected to drive the growth of the influenza diagnostic market in the coming years. Funding for influenza diagnostic research refers to financial resources provided by government agencies, institutions, and organizations to support scientific investigations focused on developing, improving, and validating methods and technologies for detecting influenza viruses. The rise in research funding is influenced by lessons from the COVID-19 pandemic and concerns about future respiratory disease outbreaks, as health authorities recognize the importance of rapid and accurate diagnostics to prevent widespread transmission and enable timely public health responses. Increased funding supports the development and commercialization of advanced testing technologies, molecular assays, point-of-care devices, and improved laboratory procedures, facilitating faster and more precise identification of influenza strains in clinical settings. For example, in October 2024, the Department of Health and Aged Care, an Australia-based government organization, announced that the Australian Government would allocate $95 million to combat avian influenza, protecting agriculture, wildlife, and the economy. Therefore, rising research funding is boosting growth in the influenza diagnostic market.

Key companies in the influenza diagnostic market are developing innovative products, such as the Lucira COVID-19 & Flu Home Test, which allows simultaneous rapid qualitative detection of multiple pathogens. The Lucira COVID-19 & Flu Home Test is a single-use, at-home test kit that provides results from self-collected nasal swabs in approximately 30 minutes. For example, in February 2023, Pfizer Inc., a US-based pharmaceutical company, received approval for this test, which can detect influenza A and B, as well as SARS-CoV-2, the virus responsible for COVID-19.

In February 2024, Thyrocare Technologies Limited, an India-based healthcare company, acquired Think Health Diagnostic Private Limited for an undisclosed sum. This acquisition expanded Thyrocare’s service offerings, enabling the company to reach more customers and increase its market share in the diagnostics sector. The acquisition also allowed Thyrocare to integrate at-home ECG testing with blood diagnostics, positioning itself as a comprehensive solution for premedical and annual health checkups. Think Health Diagnostic Private Limited is an India-based home healthcare services company specializing in telehealth, laboratory testing, and pharmacy services.

Major companies operating in the influenza diagnostic market are F. Hoffmann-La Roche Ltd., Quidel Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Hologic Inc., Becton Dickinson and Company, DiaSorin SpA, Luminex Corporation, Meridian Bioscience Inc., GenMark Diagnostics Inc., SA Scientific Ltd., Sekisui Diagnostics LLC, bioMérieux Inc., Danaher Corporation, Siemens Healthineers AG, Coris Bioconcept Sprl, Mast Group, Elitech Technology lnc., Analytik Jena AG, altona Diagnostics GmbH, Tecan Trading AG, Genome Diagnostics Pvt Ltd., Germaine Laboratories Inc., Response Biomedical Corporation, TAUNS Laboratories Inc., TRUPCR Europe Ltd., Quest Diagnostics Inc., Labcorp Employer Services Inc.

North America was the largest region in the influenza diagnostics market in 2025. Western Europe was the second largest region in the influenza diagnostics market. The regions covered in the influenza diagnostic market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the influenza diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the influenza diagnostic market by increasing costs of molecular testing reagents, diagnostic instruments, and laboratory consumables sourced through global supply chains. These impacts are most evident in molecular diagnostic and rapid test segments, particularly across asia-pacific and europe where reliance on imported components is high. Higher tariffs have increased procurement costs for hospitals and diagnostic laboratories. However, tariffs are also encouraging local manufacturing of diagnostic kits, regional supply chain development, and investment in cost-efficient testing technologies, supporting long-term market stability.

The influenza diagnostic market research report is one of a series of new reports that provides influenza diagnostic market statistics, including influenza diagnostic industry global market size, regional shares, competitors with a influenza diagnostic market share, detailed influenza diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the influenza diagnostic industry. This influenza diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Influenza diagnostics refer to tests used to detect influenza, including viral culture, serology, rapid antigen testing, reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence assays, and rapid molecular assays. Influenza, commonly known as the flu, is a contagious disease caused by the influenza virus. Three types of the virus affect humans: type A, type B, and type C. Common symptoms include fever, sore throat, cough, body aches, fatigue, and headache. The market encompasses revenues generated by establishments conducting diagnostic tests for the detection of influenza viruses.

The primary traditional diagnostic test types in influenza diagnostics include rapid influenza diagnostic tests (RIDTs), viral culture, direct fluorescent antibody (DFA) assays, serological assays, and others. RIDTs are immunoassays that detect influenza A and B viral nucleoprotein antigens in respiratory specimens and provide qualitative results (positive or negative). Molecular diagnostic tests include reverse transcription polymerase chain reaction (RT-PCR), isothermal nucleic acid amplification tests (INAAT), loop-mediated isothermal amplification assays, transcription-mediated isothermal amplification assays, and other isothermal nucleic acid amplification tests. These diagnostics are used by hospitals, clinical laboratories, diagnostic reference laboratories, academic and research institutions, and other end users.

The influenza diagnostic market includes revenue earned by test kit and reagents, and other products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.